Updates

Announcements

ImmuPharma Commences Trading on the Stuttgart Stock Exchange

Feb 28, 2013

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announces that it has been informed by Baader Bank AG that its shares are now being traded on the third segment of the Stuttgart Stock Exchange. Baader Bank AG has experience and expertise for trading in German…
CNRS Confirms Lupuzor’sTM Effectiveness

Jan 28, 2013

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration partner and the inventor of ImmuPharma’s lead compound, LupuzorTM has issued a press release confirming the effectiveness of the LupuzorTM peptide P140. LupuzorTM is ImmuPharma’s lead compound and potential blockbuster drug…
ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

Nov 20, 2012

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to today outline the key abstract information presented on Wednesday 14 November at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which was held this week. The ACR Annual Scientific Meeting is the premier worldwide scientific meeting devoted…
ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

Nov 15, 2012

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which is being held between 11 – 14 of November. ImmuPharma will be presenting on Wednesday 14 November 2012. The ACR…
Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

Oct 8, 2012

ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun further clinical trials with the next generation of “polyplexed Nucant”. The first patients have started dosing in this new Phase I/ II clinical trial. This “polyplexed Nucant”…
ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012

Sep 7, 2012

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the Rodman and Renshaw Annual Global Investment Conference on Tuesday 11 September 2012 at the Waldorf Astoria in New York City. Tracy Weimar, Vice President, Operations and Finance will present an…
ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012

Jul 13, 2012

ImmuPharma PLC (LSE: IMM) (“ImmuPharma” or the “Company”), the specialist discovery and development pharmaceutical company, has been voted “Best Medical Research and Development Company, Europe” at The New Economy Pharmaceutical & Healthcare Awards 2012. This is the second time ImmuPharma has won this prestigious award, the first being in 2010 when voted “Best Drug Development…
ImmuPharma PLC Appoints Cenkos Securities as Joint Broker

Jul 3, 2012

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug development company, is pleased to announce the appointment of Cenkos Securities plc, as Joint Broker to the Company, with immediate effect. Commenting on the appointment of Cenkos, Dimitri Dimitriou, ImmuPharma’s Chief Executive Officer said: “We are delighted to be working more closely with Cenkos. The Cenkos team brings…
PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011

Mar 27, 2012

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2011.
ImmuPharma PLC Appoints Head of Investor Relations

Feb 29, 2012

ImmuPharma PLC (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations.
ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA

Nov 3, 2011

ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status of its Lupus drug candidate Lupuzor™
ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger

Oct 21, 2011

ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon Inc (Cephalon), its licensee for Lupuzor™, it has regained rights to Lupuzor™, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd (Teva).

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

ImmuPharma Commences Trading on the Stuttgart Stock Exchange

CNRS Confirms Lupuzor’sTM Effectiveness

ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012

ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012

ImmuPharma PLC Appoints Cenkos Securities as Joint Broker

PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011

ImmuPharma PLC Appoints Head of Investor Relations

ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA

ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger